GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly has ... trials front Lilly announced plans to start a five-year real-world evidence study involving tirzepatide, the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug ...